Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘ASCO 2014 ABT-199’

One of the things I most enjoy in cancer research is hearing wonderful patient stories from oncologists who are at the coal face of clinical trials. They get to deal with death and dying every day and like those in Pharma R&D, also live for the successes, the drugs that make it through pipeline despite great odds against them and make a meaningful impact on the daily lives of ordinary people.

We’ve all heard topline data presented at medical conferences around the world, but what the summary data can’t tell you is how a drug can impact people in ways that are clinically meaningful yet are more obtuse to capture in the aggregate. This is why case studies at CME sessions are increasingly popular, because they add value and context to common issues in a way that a Kaplan-Meier curve can never do.

Zydelig_logoWith the flurry of recent US and EU approvals for obinutuzumab (Gazyva), ibrutinib (Imbruvica) and the newest kid on the block, idelalisib (Zydelig), in CLL and indolent lymphomas, I wanted to take a look at these drugs from a different perspective.

A reader wrote in asking which of these new agents would emerge the winner and why?

Today’s post therefore offers some thoughts on the emerging CLL landscape now that we are shifting from new product development to the marketplace.

Drugs mentioned: Gazyva, Imbruvica, Zydelig, ABT–199/GDC–0199, Arzerra, IPI–145, CTL–019
Companies: Roche/Genentech, J&J/Pharmacyclics, Gilead, GSK, Infinity, Novartis

To learn more, you can sign up or sign in below.

Welcome to ASCO 2014 (#ASCO14), and this year’s annual meeting of the American Society of Clinical Oncology (ASCO) and the world’s largest cancer conference.

It’s the Super Bowl of cancer conferences – the meeting you not only have to be at if you’re in the field, but where you want to have your data presented. The press room is truly multinational.

The weather I have to say is glorious in Chicago, it’s probably the best time of year to visit, but as anyone who has ever been to ASCO knows, it’s an all consuming meeting and you never have any chance to visit the sights, although the travel department has kindly provided a room with a view.

This year we’ll be writing daily blog posts that provide rolling coverage – as and when the opportunity presents – we’ll be updating the post with news, commentary, and the occasional picture or clip from an interview.

Today, despite being primarily a travel day, we made it to a couple of the poster highlights sessions.

Sadly, with flights, hotels and bar bills to pay, the ASCO coverage is for subscribers only. The first of our live blogs begins below. It will probably kill us to do this, but here goes…..we’re kicking off with some commentary on the poster highlights sessions.

error: Content is protected !!